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A number of reports including a recent publication in Osteoarthritis and Cartilage have suggested that
smokers have a lower than expected prevalence of osteoarthritis (OA) than nonsmokers. We review the
evidence linking smoking with OA, suggest approaches whereby the direct and indirect effects of
smoking on OA might be distinguished, highlight two diseases, ulcerative colitis and Parkinson's disease,
where smoking is protective, discuss mechanisms by which nicotine might act and lastly explore the
association of smoking with enhanced musculoskeletal pain.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.In analyzing osteoarthritis (OA) data from a large US survey, we
noted, even after adjustment for their thin body habitus, that
smokers had a decreased prevalence of knee OA compared with
non-smokers1. We corroborated this inverse relationship between
smoking and OA in the Framingham Study in longitudinal ana-
lyses2. This led to a series of studies on smoking and OA.
Why study smoking and OA? Even if smokers were protected
against OA, we would never advocate that persons smoke tobacco
products given the multitude of negative effects of smoking on
health. Rather, if we were to document favorable effects of tobacco
on OA, this might provide an opportunity to identify constituents of
tobacco smoke that have favorable effects on disease and to test
these as treatments.
In this editorial we shall review the evidence that has accumu-
lated since our original report, present new epidemiologic ap-
proaches to addressing this question and review associations of
smoking with two other diseases where smoking has been found
to be protective and with musculoskeletal pain.
Epidemiologic evidence linking smoking with osteoarthritis
A recent meta-analysis3 on smoking and hand, knee, hip and
spine OA summarized data from 48 published studies. Overall,
there was an inverse relationship between smoking and OA (odds
ratio ¼ 0.87; 95% CI, 0.80e0.94). While a protective association of
smoking and OAwas seen in all subgroups of studies, it reached sig-
niﬁcance only in case control studies (where there were more
studies) and failed to reach signiﬁcance in cohort studies. The pro-
tective association was especially noteworthy for studies of knee
OA where large numbers of subjects were evaluated. Among the
case control studies, the association was stronger in hospital-
based than community-based studies, with community based
studies usually providing less biased ﬁndings, but the odds ratio
examining the association of smoking with OA was protective in
studies in which OA was deﬁned radiographically. No publicationternational. Published by Elsevier Lbias was found. There was a stronger protective association for cur-
rent smokers and no association of smoking with OA among past
smokers.
Smoking has negative effects on disc disease, and spinal OA
studies were included in this meta-analysis; these studies showed
that smokers had an increased risk of spinal OA and this biased the
meta-analysis toward the null (even though ﬁndingswere not null).
Some studies included adjusted for BMI and others did not.
Smokers are thinner than non-smokers, and obesity is a major
risk factor for OA. The authors showed that the protective effect
was greater when BMI was not adjusted for, but even when BMI
was included in analyses, smokers still had a lower risk of OA
than non-smokers3. Since this meta-analysis, investigators from a
large epidemiologic cohort study from Singapore using as cases
persons with total knee replacement for OA have reported in Oste-
oarthritis and Cartilage also that smokers have a lower risk of OA
than non-smokers4.
In our view, the preponderance of evidence suggests that
smokers are modestly protected against developing radiographic
OA in the knee and hip.
There is no clearcut relationship of current smoking and carti-
lage loss in those without OA as assessed by MRI. One study5 has
suggested that among those from families with an OA history, cur-
rent smoking accelerated cartilage loss, whereas it had no effect on
such loss in others.
Methodologic issues that complicate the study of smoking
and OA
Most epidemiologic studies examining the association between
smoking and the risk of OA have adjusted for BMI; this practice,
however, may not be appropriate when the goal of the study is to
assess the total effect of smoking on the risk of OA. In the causal di-
agram below [Fig. 1], we assume that there are two mechanisms
through which smoking can affect the risk of knee OA: one istd. All rights reserved.
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Fig. 1. Causal Diagram depicting interrelationship of smoking, BMI, other covariates
(i.e., confounders and other risk factors) and development of OA.
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smoking / BMI / OA); another is smoking's effect on OA not
through BMI (i.e., direct effect: smoking/ OA). The total effect of
smoking on risk of OA is the effect through all potential causal path-
ways (i.e., smoking/ BMI/ OA and smoking/ OA). Thus, BMI is
a mediator, not a confounder. This assumption is supported by
empirical evidence which demonstrates that smokers are thinner
than non-smokers6. On the other hand, to be a potential
confounder, BMI would have to inﬂuence a person's smoking status
and, to our knowledge, few, if any, studies have found this. Adjust-
ing for BMI blocks one biological mechanism through which smok-
ing affects the risk of OA (i.e., its indirect effect). Consequently, the
effect one obtains from such an analysis is a direct effect of smoking
(i.e., an effect of smoking on ROA not through its effect on BMI). Ul-
timately, examining the risk of OA in smokers vs non-smokers
without adjusting for BMI provides a better estimate of the total ef-
fect of smoking on OA.
In addition, adjusting for BMI (indicated by a box around ‘BMI’ in
Fig. 2) may introduce collider-stratiﬁcation bias limiting the accu-
racy of the estimate of the direct effect of smoking on the risk of
OA. Studies have shown that smokers tend to have a low BMI. If
we found a thin non-smoker, we would expect that that person
must have been exposed to other risk factor(s) for thinness (e.g.,
a gene). Adjusting for BMI at which two causal paths collide, i.e.,
smoking /low BMI and gene / low BMI, creates a non-causal
path from smoking to OA (i.e., smoking d other risk
factors/ OA). Without appropriately adjusting for other risk fac-
tors (e.g., gene), the direct effect of smoking on the risk of OA is sus-
ceptible to potential collider-stratiﬁcation bias7,8. Newly developed
statistical models can be used to appropriately estimate the direct
and indirect effect of a risk factor on OA7,8. Furthermore, assess-
ment of the direct effect of smoking on OA may be more relevant
from the point of view of treatment implications than evaluating
the total effect which includes the indirect effect of smoking on
thinness.Smoking BMI OA
Confounders
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Fig. 2. Causal diagram depicting evaluation of the effect of smoking on risk of ROA.
Adjusting for BMI made previously independent variables of smoking and other risk
factors correlated as depicted by the dashed line.Favorable effects of smoking on ulcerative colitis and
Parkinson's disease
Cigarette smoke has over 4,500 constituents and Identifying
which one causes a given health effect is exceedingly challenging.
Immune and inﬂammatory effects of smoking could be ascribed
to a number of constituents, but nicotine's effects are similar to
and perhaps stronger than the effects of tobacco smoke in general,
suggesting that many of the immune inﬂammatory effects are nico-
tine related. Many of nicotine's complex biologic effects are medi-
ated by nicotinic acetylcholine (Ach) receptors on both neuronal
and non-neuronal cells9. Cells of the immune system, a major
source of inﬂammatory cytokines, express the main nicotine sensi-
tive acetylcholine receptor, the a7 receptor, and these cells are
functionally responsive to nicotine. The net effect of cholinergic
stimulation of these receptors is anti-inﬂammatory, a decreased
production of cytokines that mediate the inﬂammatory response.
However, effects may vary by cell type and tissue9.
Investigators examining risk factors for ulcerative colitis noted
that smokers had a lower risk of disease than non-smokers10.
This was in contrast to Crohn's disease where the opposite effect
was seen. Smokers who stopped smoking experienced a ﬂare in ul-
cerative colitis, and ex-smokers who recommenced smoking noted
a reduction in disease activity. Nicotine was implicated as the cause
of these changes. Some clinical trials testing nicotine as a therapeu-
tic agent showed that those given nicotine patches experienced a
reduction in disease activity and even evidence of histologic
improvement in the gastrointestinal mucosa11. Even so, some trial
results were not positive and nicotine's side effects limited thera-
peutic use. Studies are exploring the efﬁcacy of nicotine adminis-
tered directly to the gastrointestinal tract through enemas to
minimize side effects.
Parkinson's disease is a degenerative nervous systemmotor dis-
order caused by depletion of dopamine from regions of the brain
that control motor function. Non-smoking is among the strongest
known disease risk factors. A recent meta-analysis showed a 66%
reduction in Parkinson's disease risk among current compared to
never-smokers12. While nicotine is a prime candidate as the con-
stituent of smoke that protects against disease, other candidates
include TMN which protects against neurodegeneration in mice13.
The effect of nicotine appears to be mediated through its effect
on neuronal acetylcholine receptors. In non-human primate
models, nicotine administration reduces the onset of dyskinesia.
Trials are underway in humans testing nicotine preparations.
Effects of smoking on musculoskeletal pain
Smokersmore often havemusculoskeletal (MSK) pain than non-
smokers14,15. Furthermore, among persons with MSK pain, smokers
have more severe and persistent pain than non-smokers.
There are several explanations for the association between
smoking and chronic pain. First, smoking can lead to downregula-
tion of the hypothalamic pituitary axis which may increase pain
sensitivity. Second, the dorsal root ganglion is richly innervated
with nicotine sensitive acetylcholine receptors. Lastly, in the central
nervous system, nicotine may act through its ability to stimulate
the release of excitatory amino acids with pro-nociceptive effects16.
Thus, smokingmay have contradictory effects on OA. On the one
hand, effects mediated through the nicotine sensitive acetylcholine
receptor may help prevent disease. On the other hand, similar re-
ceptors on neuronal cells may, when excited, induce musculoskel-
etal pain. The recent meta-analysis of smoking and mostly
radiographic OA reported that smokers had less disease than non-
smokers, but interestingly, in this meta-analysis, smokers had a
modestly increased risk (OR ¼ 1.25) of painful OA.
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While smokers probably have a lower risk of radiographic OA
than non-smokers, smokers also have a higher risk of musculoskel-
etal pain. The clinical relevance of any smoking effect in OA given
the possible adverse effects on symptoms is unclear.
Much remains unresolved in the study of smoking and OA. First,
the protective association with radiographic OA is not a strong one
and may be altered by analytic approaches that assume that thin-
ness plays a mediating role in the relationship between smoking
and OA. Also unresolved is whether any favorable effect of smoking
on OA might be mediated differently than an adverse effect of
smoking on pain. If the effects of smoking on OAwere, for example,
not mediated by nicotine but nicotine caused heightened pain
sensitivity, then a treatment opportunity might exist.
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